- Optimi Health (CSE:OPTI) received three export permits from Health Canada to supply GMP MDMA and psilocybin to Australia
- The microcap psychedelics manufacturer announced these necessary export permits are for its capsules to be used in patients participating in Australia’s authorized prescriber scheme
- Starting with an initial shipment of 160 doses, this marks Optimi’s commercial entry into Australia with its GMP-certified psychedelic medicines for eligible patients dealing with PTSD and treatment-resistant depression
- Optimi Health Corp. stock last traded at $0.32 per share
Optimi Health (CSE:OPTI) received three export permits from Health Canada to supply GMP MDMA and psilocybin to Australia.
The microcap psychedelics manufacturer announced these export permits are for its capsules to be used in patients participating in Australia’s authorized prescriber scheme.
Starting with an initial shipment of 160 doses, this marks Optimi’s commercial entry into Australia with its GMP-certified psychedelic medicines for eligible patients dealing with PTSD and treatment-resistant depression. Optimi’s MDMA and psilocybin capsules will be exported from the company’s facility in Canada, leveraging Optimi’s recent Drug Establishment Licence.
After the Therapeutic Goods Administration reclassification of MDMA and psilocybin last year, Australia became the first country globally to allow the regulated use of these substances under medical supervision in a therapeutic context. The capsules will be imported by Mind Medicine Australia and then distributed to licensed pharmacies around the country.
The company added that this initiative is important for collecting real world evidence and patient-reported outcomes, which is intended to contribute meaningful data to a growing body of research that supports the therapeutic potential of Optimi’s GMP MDMA and psilocybin capsules.
“Receiving the export permits from Health Canada is a great achievement for both the Optimi team and shareholders alike,” JJ Wilson, the company’s co-founder and chairman, said in a news release. “It underscores the company’s commitment to advancing our global supply efforts to provide medical professionals in Australia with the tools they need to offer psychedelic-assisted therapies to those suffering with PTSD and treatment-resistant depression.”
Optimi Health is a Health Canada-licensed psychedelics pharmaceutical manufacturer focused on controlled substances such as botanical psilocybin and MDMA and functional mushrooms that focus on the health and wellness markets. The company is planning to launch its prescriber portal soon for Australian psychiatrists seeking more information about its drug candidates.
Optimi Health Corp. stock (CSE:OPTI) last traded at $0.32 per share. The stock has added 51.16 per cent year-over-year, but remains down 65.96 per cent since inception in 2021.
Join the discussion: Learn what other investors are saying about this psychedelic stock on the Optimi Health Corp. Bullboard, and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top photo: Optimi Health)
